OncoMatch/Clinical Trials/NCT05516914
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Is NCT05516914 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for malignant tumors.
Treatment: LBL-007 · Tislelizumab · Cisplatin · Gemcitabine Hydrochloride for · Docetaxel — This trial is an open and multicenter phase Ib/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: unmarketed clinical research drugs or treatments
Have received other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Subject has adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify